0001628280-26-024906
SEC filingSpyre Therapeutics announced preliminary Q1 2026 cash position of $741 million and terminated its at-the-market common stock offering prospectus effective April 13, 2026.
Spyre Therapeutics disclosed preliminary unaudited balance sheet information indicating a strong liquidity position with $741 million in cash, cash equivalents, and marketable securities as of March 31, 2026. This figure incorporates $30 million from legacy asset dispositions during the quarter, though $23 million of that is slated for payout to contingent value rights holders in Q2 2026, signaling near-term cash outflow. These preliminary numbers have not undergone audit or review by the company's independent accountants and remain subject to finalization, carrying risk of material variance. Concurrently, the company terminated its ATM Prospectus effective April 13, 2026, halting any at-the-market sales of its $0.0001 par value common stock under the existing Sales Agreement with TD Securities (USA) LLC, dated September 6, 2024. The Sales Agreement itself persists, allowing potential resumption with a new prospectus or supplement. This dual disclosure underscores robust current liquidity alongside a strategic pause in equity issuance, potentially preserving cash runway while signaling no immediate need for dilutionary financing.